Mark Baldry - 31 Oct 2023 Form 4 Insider Report for X4 Pharmaceuticals, Inc (XFOR)

Role
Chief Commercial Officer
Signature
/s/ Adam S. Mostafa, attorney-in-fact
Issuer symbol
XFOR
Transactions as of
31 Oct 2023
Net transactions value
$0
Form type
4
Filing time
02 Nov 2023, 17:00:56 UTC
Previous filing
04 Nov 2022
Next filing
03 Nov 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XFOR Common Stock Award $0 +34,947 $0.000000 34,947 31 Oct 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares earned upon the vesting of performance-based restricted stock units. The Compensation Committee of the Board of Directors of the Issuer certified the achievement of a performance condition, which occurs upon FDA acceptance of a new drug application for mavorixafor.